Insider Sells $753K Nuvation Bio Stock

On June 23, 2026, Stacy Markel, Chief People Officer at Nuvation Bio Inc., exercised 125,000 stock options for Class A Common Stock. Markel then sold these shares in a transaction valued at approximately $753,000, as reported in a SEC Form 4 filing. This move provided significant liquidity for Markel by converting derivative holdings into cash. The transaction was part of a pre-established trading plan adopted in December 2025. This sale represents Markel's sole disposition of company stock within the last five years of reporting history. Despite the sale, Markel retains control over 629,810 outstanding options. Nuvation Bio is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapeutics. Their pipeline includes small molecule drugs and a proprietary drug-drug conjugate platform aimed at treating various cancers, including ER-positive breast and ovarian cancers.